Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial.
about
Differential inflammatory response to inhaled lipopolysaccharide targeted either to the airways or the alveoli in manLPS-induced lung inflammation in marmoset monkeys - an acute model for anti-inflammatory drug testingAnti-TNF inhibits the airways neutrophilic inflammation induced by inhaled endotoxin in human.Vulnerable COPD patients with comorbidities: the role of roflumilast.Low-dose endotoxin inhalation in healthy volunteers--a challenge model for early clinical drug development.Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model--a clinical trial.Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary diseaseTreatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.Challenge models to assess new therapies in chronic obstructive pulmonary disease.Roflumilast : the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD.Roflumilast: A Review in COPD.Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injuryRoflumilast: systemic therapy for chronic obstructive pulmonary disease.
P2860
Q28383064-4E13CB5C-0D84-4199-9E24-F0BC0BB07A60Q28482881-7CAD7BA1-29E0-4AE4-A21C-4DEB0F46526AQ34537628-476677A2-94DB-4DE6-9303-A1CA84A7FCB6Q34566361-D9E6EC2E-1A1D-4219-AA5D-E307A156AA79Q34640736-2C40D765-E589-47B1-BEF5-F1DB85286306Q34997388-76391BD9-4C96-4BE5-94C6-E75A99C29E3AQ35743384-F586A8AE-4C7E-4547-BAD2-AA3E560310EFQ35958704-82B6482A-5B80-46C2-822B-22625846A9FDQ37732234-DADB022E-AAAC-41B1-BD59-D458C3C583C0Q37778289-FBBFFE23-8A2E-4A35-8390-F826913FDFD3Q38051306-881AE5FD-24F9-4C87-ADE3-17B6D7E80CA2Q38137141-D6BF0C2F-84BF-4853-89BD-B950C8CB7AA0Q38580536-841DD544-3175-4344-B3D3-2BC5C8C492EEQ41429523-828F3D3F-FC44-4971-A125-B215A3470057Q43061644-3D30E705-F096-4162-AF71-D295A6B74EDF
P2860
Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Roflumilast attenuates pulmona ...... ized placebo-controlled trial.
@ast
Roflumilast attenuates pulmona ...... ized placebo-controlled trial.
@en
Roflumilast attenuates pulmona ...... ized placebo-controlled trial.
@nl
type
label
Roflumilast attenuates pulmona ...... ized placebo-controlled trial.
@ast
Roflumilast attenuates pulmona ...... ized placebo-controlled trial.
@en
Roflumilast attenuates pulmona ...... ized placebo-controlled trial.
@nl
prefLabel
Roflumilast attenuates pulmona ...... ized placebo-controlled trial.
@ast
Roflumilast attenuates pulmona ...... ized placebo-controlled trial.
@en
Roflumilast attenuates pulmona ...... ized placebo-controlled trial.
@nl
P2093
P921
P1476
Roflumilast attenuates pulmona ...... mized placebo-controlled trial
@en
P2093
Dirk Bredenbroeker
Frank Schaumann
Kerstin Schoenfeld
Mehyar Lavae-Mokhtari
Meike Mueller
Norbert Krug
Robert Hermann
P304
P356
10.1016/J.PUPT.2008.02.002
P577
2008-02-21T00:00:00Z